May 28, 2020

May 27, 2020

Subscribe to Latest Legal News and Analysis

May 26, 2020

Subscribe to Latest Legal News and Analysis

Biotechnology, Life Sciences, Food and Drug Law News

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

Date Title Organization
3
Sep
Government Issues New Rules for Religious Employers, But Health Plans, Third Party Administrators (TPAs), and Pharmacy Benefits Managers (PBMs) are still on the Hook to Provide Contraceptive Coverage Mintz
2
Sep
EU Court Of Justice Further Clarifies Definition Of Medicinal Products – And Raises New Questions Covington & Burling LLP
2
Sep
China Issues Multiple Final Rules and Proposals to Implement Recent Revisions to its Core Medical Device Regulation Covington & Burling LLP
2
Sep
Summary of FDA Advertising and Promotion Enforcement Activities – September 2, 2014 Covington & Burling LLP
2
Sep
The Increasingly Murky World of 340B Drug Discount Program: What’s Next? Mintz
2
Sep
Two-Party Market: Presumption of Confusion and Injury McDermott Will & Emery
29
Aug
Pharmacies Avoid False Claims Act Suit: Fox Rx Inc. v. Omnicare Inc. et al. Covington & Burling LLP
28
Aug
Hawaii G-M-O: Kauai County GMO Regs Struck Down in Federal Court Mintz
28
Aug
Third Circuit Holds Irreparable Harm May Not Be Presumed In Lanham Act False Advertising Cases To Establish Entitlement To Injunctive Relief Proskauer Rose LLP
27
Aug
Genus Claims Require Disclosure of “Representative Species Encompassing the Breadth of the Genus” McDermott Will & Emery
27
Aug
Selection Invention Found Unpatentable for Obviousness-Type Double Patenting Sterne, Kessler, Goldstein & Fox P.L.L.C.
27
Aug
Tennessee Employer Gets New Trial to Prove Drug Tests Were Not Medical Examinations or Disability-Related Inquiries Jackson Lewis P.C.
26
Aug
Health Care Law Update - August 25, 2014 Mintz
25
Aug
Northern District of Illinois Court Answers the Question: What KIND of Juice Did They Say It Was? Proskauer Rose LLP
25
Aug
FDA Notifies Congress of Framework for Long-Awaited Guidance on Laboratory Developed Tests and Issues Final Guidance on Companion Diagnostics Mintz
25
Aug
FDA Issues Draft Guidance on De Novo Process Barnes & Thornburg LLP
25
Aug
Medical Device Update: FDA Issues Draft Guidance on Streamlined De Novo Classification Process Morgan, Lewis & Bockius LLP
25
Aug
Prescription Drugs: Refocusing the False Claims Act Microscope on the Rest of the Transaction Mintz
25
Aug
Physicians Write Letter to FDA Regarding Biosimilar Naming Concerns McDermott Will & Emery
25
Aug
FDA’s Announced Framework for Regulating Laboratory Developed Tests (LDTs) Leaves Open Many Questions Covington & Burling LLP

Pages

LATEST LEGAL NEWS & ANALYSIS

TRENDING LEGAL ANALYSIS